Literature DB >> 21077702

An experimental investigation of masking in the US FDA adverse event reporting system database.

Hsin-wei Wang1, Alan M Hochberg, Ronald K Pearson, Manfred Hauben.   

Abstract

BACKGROUND: A phenomenon of 'masking' or 'cloaking' in pharmacovigilance data mining has been described, which can potentially cause signals of disproportionate reporting (SDRs) to be missed, particularly in pharmaceutical company databases. Masking has been predicted theoretically, observed anecdotally or studied to a limited extent in both pharmaceutical company and health authority databases, but no previous publication systematically assesses its occurrence in a large health authority database.
OBJECTIVE: To explore the nature, extent and possible consequences of masking in the US FDA Adverse Event Reporting System (AERS) database by applying various experimental unmasking protocols to a set of drugs and events representing realistic pharmacovigilance analysis conditions.
METHODS: This study employed AERS data from 2001 through 2005. For a set of 63 Medical Dictionary for Regulatory Activities (MedDRA®) Preferred Terms (PTs), disproportionality analysis was carried out with respect to all drugs included in the AERS database, using a previously described urn-model-based algorithm. We specifically sought masking in which drug removal induced an increase in the statistical representation of a drug-event combination (DEC) that resulted in the emergence of a new SDR. We performed a series of unmasking experiments selecting drugs for removal using rational statistical decision rules based on the requirement of a reporting ratio (RR) >1, top-ranked statistical unexpectedness (SU) and relatedness as reflected in the WHO Anatomical Therapeutic Chemical level 4 (ATC4) grouping. In order to assess the possible extent of residual masking we performed two supplemental purely empirical analyses on a limited subset of data. This entailed testing every drug and drug group to determine which was most influential in uncovering masked SDRs. We assessed the strength of external evidence for a causal association for a small number of masked SDRs involving a subset of 29 drugs for which level of evidence adjudication was available from a previous study.
RESULTS: The original disproportionality analysis identified 8719 SDRs for the 63 PTs. The SU-based unmasking protocols generated variable numbers of masked SDRs ranging from 38 to 156, representing a 0.43-1.8% increase over the number of baseline SDRs. A significant number of baseline SDRs were also lost in the course of our experiments. The trend in the number of gained SDRs per report removed was inversely related to the number of lost SDRs per protocol. Both the number and nature of the reports removed influenced the number of gained SDRs observed. The purely empirical protocols unmasked up to ten times as many SDRs. None of the masked SDRs had strong external evidence supporting a causal association. Most involved associations for which there was no external supporting evidence or were in the original product label. For two masked SDRs, there was external evidence of a possible causal association.
CONCLUSIONS: We documented masking in the FDA AERS database. Attempts at unmasking SDRs using practically implementable protocols produced only small changes in the output of SDRs in our analysis. This is undoubtedly related to the large size and diversity of the database, but the complex interdependencies between drugs and events in authentic spontaneous reporting system (SRS) databases, and the impact of measures of statistical variability that are typically used in real-world disproportionality analysis, may be additional factors that constrain the discovery of masked SDRs and which may also operate in pharmaceutical company databases. Empirical determination of the most influential drugs may uncover significantly more SDRs than protocols based on predetermined statistical selection rules but are impractical except possibly for evaluating specific events. Routine global exercises to elicit masking, especially in large health authority databases are not justified based on results available to date. Exercises to elicit unmasking should be driven by prior knowledge or obvious data imbalances.

Entities:  

Mesh:

Year:  2010        PMID: 21077702     DOI: 10.2165/11584390-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  10 in total

1.  Practical pharmacovigilance analysis strategies.

Authors:  A Lawrence Gould
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Oct-Nov       Impact factor: 2.890

2.  A decade of data mining and still counting.

Authors:  Manfred Hauben; G Niklas Norén
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

Review 3.  Perspectives on the use of data mining in pharmaco-vigilance.

Authors:  June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  The role of data mining in pharmacovigilance.

Authors:  Manfred Hauben; David Madigan; Charles M Gerrits; Louisa Walsh; Eugene P Van Puijenbroek
Journal:  Expert Opin Drug Saf       Date:  2005-09       Impact factor: 4.250

5.  'Extreme duplication' in the US FDA Adverse Events Reporting System database.

Authors:  Manfred Hauben; Lester Reich; James DeMicco; Katherine Kim
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions.

Authors:  Yannick Arimone; Ghada Miremont-Salamé; Françoise Haramburu; Mathieu Molimard; Nicholas Moore; Annie Fourrier-Réglat; Bernard Bégaud
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

Review 7.  Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Quantitative signal detection for vaccines: effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports database.

Authors:  Ziad Zeinoun; Harry Seifert; Thomas Verstraeten
Journal:  Hum Vaccin       Date:  2009-09-07

9.  Omeprazole-induced intractable cough.

Authors:  Mehran Howaizi; Christian Delafosse
Journal:  Ann Pharmacother       Date:  2003-11       Impact factor: 3.154

10.  Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

Authors:  Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  10 in total
  17 in total

1.  Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Authors:  Alice Capogrosso Sansone; Irma Convertino; Maria Teresa Galiulo; Stefano Salvadori; Stefania Pieroni; Tamara Knezevic; Stefania Mantarro; Alessandra Marino; Manfred Hauben; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

Review 2.  Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?

Authors:  Preciosa M Coloma; Gianluca Trifirò; Vaishali Patadia; Miriam Sturkenboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

3.  A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.

Authors:  Francesco Salvo; Florent Leborgne; Frantz Thiessard; Nicholas Moore; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

4.  Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.

Authors:  James R Rogers; Ameet Sarpatwari; Rishi J Desai; Justin M Bohn; Nazleen F Khan; Aaron S Kesselheim; Michael A Fischer; Joshua J Gagne; John G Connolly
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

5.  A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality.

Authors:  François Maignen; Manfred Hauben; Jean-Michel Dogné
Journal:  Ther Adv Drug Saf       Date:  2017-05-05

6.  Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®).

Authors:  François Montastruc; Francesco Salvo; Mickaël Arnaud; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

7.  Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.

Authors:  Rachel Vickers-Smith; Jiangwen Sun; Richard J Charnigo; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-11-02       Impact factor: 4.492

8.  Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France.

Authors:  Antoine Pariente; Paul Avillach; Francesco Salvo; Frantz Thiessard; Ghada Miremont-Salamé; Annie Fourrier-Reglat; Françoise Haramburu; Bernard Bégaud; Nicholas Moore
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

Review 9.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738

10.  Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.

Authors:  Birgitta Grundmark; Lars Holmberg; Hans Garmo; Björn Zethelius
Journal:  Eur J Clin Pharmacol       Date:  2014-03-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.